文献速递产科

围受孕期或妊娠期接种人乳头瘤病毒疫苗后的母婴结局

Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
PubMed 文献 · Obstet Gynecol · 2017-01-01

基于疫苗安全数据链的回顾性观察性队列研究,纳入2007年1月1日至2013年9月1日单胎活产的13-27岁参保女性,比较围受孕期或妊娠期接种四价人乳头瘤病毒疫苗(4vHPV)与末次月经前4-18个月接种者的不良产科事件、不良出生结局及主要结构出生缺陷风险。妊娠期接种与不良产科事件及出生结局风险增加无关,早产和主要结构出生缺陷在暴露组与对照组间无显著差异,围受孕期暴露结果相似。结论认为妊娠期或围受孕期无意接种4vHPV与不良妊娠或出生结局无关。

要点

  • 妊娠期接种4vHPV与不良产科事件及出生结局风险增加无关。
  • 妊娠期接种组早产7.9% vs 对照期接种组7.6%(调整相对风险0.97,95%CI 0.72-1.3)。
  • 妊娠期接种组主要结构出生缺陷2.0% vs 对照期接种组1.8%(调整患病率比1.0,95%CI 0.52-1.9)。

核心结论

  • 妊娠期或围受孕期无意接种四价人乳头瘤病毒疫苗与不良妊娠或出生结局无关。

研究设计与样本

  • 回顾性观察性队列研究,使用疫苗安全数据链的管理与医疗保健数据。
  • 纳入2007年1月1日至2013年9月1日单胎活产的13-27岁参保女性。
  • 共92,579名可能符合条件的孕妇中,720名在围受孕期接种4vHPV,638名在妊娠期接种,8,196名在对照期接种。
  • 围受孕期定义为末次月经前2周至后2周;对照期为末次月经前4-18个月。
  • 采用泊松分布的广义线性模型估计相对风险,并纳入倾向评分。

主要发现

  • 妊娠期接种4vHPV与不良产科事件及出生结局风险增加无关。
  • 妊娠期接种组早产7.9% vs 对照期接种组7.6%(调整相对风险0.97,95%CI 0.72-1.3)。
  • 妊娠期接种组主要结构出生缺陷2.0% vs 对照期接种组1.8%(调整患病率比1.0,95%CI 0.52-1.9)。
  • 围受孕期接种4vHPV的结果与妊娠期接种相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether quadrivalent human papillomavirus vaccine (4vHPV) administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects. METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13-27 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received 4vHPV during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received 4vHPV 4-18 months before their last menstrual period. We examined risks of gestational diabetes, hypertensive disorders of pregnancy, chorioamnionitis, preterm birth, small-for-gestational-age birth, and selected major structural birth defects in offspring. We estimated relative risks associated with receipt of 4vHPV during the periconceptional period, during pregnancy, and both exposure periods combined using a generalized linear model with Poisson distribution including a propensity score that included relevant maternal demographic and pregnancy characteristics. RESULTS: Of 92,579 potentially eligible pregnant women, 720 received 4vHPV during the periconceptional period, 638 received 4vHPV during pregnancy, and 8,196 received 4vHPV during the comparison period. Administration of 4vHPV during pregnancy was not associated with increased risk of adverse obstetric events, birth outcomes. Preterm birth occurred in 7.9% of pregnancies with vaccine exposures during pregnancy compared with 7.6% of pregnancies with vaccination in the comparison period (adjusted relative risk 0.97, 95% CI 0.72-1.3). Major structural birth defects were diagnosed in 2.0% of pregnancies with vaccine exposure during pregnancy compared with 1.8% of pregnancies with vaccine exposure during the comparison period (adjusted prevalence ratio 1.0, 95% CI 0.52-1.9). Results were similar for 4vHPV exposure during the periconceptional period. CONCLUSION: Quadrivalent HPV vaccine inadvertently administered in pregnancy or during the periconceptional period was not associated with adverse pregnancy or birth outcomes.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lipkind HS, Vazquez-Benitez G, Nordin JD, et al. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017. PMID: 28796684. doi:10.1097/AOG.0000000000002191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。